Trial Profile
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (SCT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2023 Number of treatment arms have been reduced from 2 to 1 by the removal of Experimental: Arm 1.
- 03 Nov 2022 Planned End Date changed from 1 Jun 2023 to 30 May 2024.
- 28 Dec 2021 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.